Summary
Other Scenarios:
- BAX - JNJ
- BAX - MDT
- JNJ - ARTC
- MDT - ARTC
| Buyer: | Baxter International Inc (BAX) | Last Price: | 54.08 | Market Cap.: | 30.73B |
|---|---|---|---|---|---|
| Target: | Arthrocare Corporation (ARTC) | Last Price: | 24.60 | Market Cap.: | 675.19M |
Lines of Business Summary:
- Baxter International Inc (BAX) competes in 1 industry and 183 product/service groups
- Arthrocare Corporation (ARTC) competes in 1 industry and 20 product/service groups
- A combined entity will have 0% Product/Service Group overlap
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
731 |
Biopharmaceuticals |
|
334 | |
Healthcare Services |
|
122 | |
Medical Devices |
|
|
177 |
Nutritional Health |
|
25 | |
Outsourced Biomedical Services |
|
39 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 164)
|
Target (Total: 30)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 13)
|
Target (Total: 0)n/a |
Buyer (Total: 15)
|
Target (Total: 1)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 48,000 | 1,407 |
| Revenue Per Employee | 295,476.2 | 260,198.3 |
| Total Revenue | 3,388.0 | 92.9 |
| Total Expenses | 2,656.0 | 75.5 |
Other Revenue
|
n/a | n/a |
Cost of Revenue
|
1,674.0 | 26.7 |
SG&A Expense
|
752.0 | 38.7 |
Research & Development
|
269.0 | 7.6 |
Other Operating Expense
|
-57.0 | 1.1 |
Operating Income
|
732.0 | 17.4 |
Unusual Income
|
n/a | 0.2 |
LT Debt to Capital
|
39.61 | n/a |
Fwd P/E
|
11.99 | 17.09 |
Fwd P/Rev
|
2.17 | 1.85 |
| Book Value | 6,725.0 | 322.3 |
Curr Portion of LTD/Cap Lease
|
485.0 | n/a |
Individual Company Summary
Focused
Buyer
Focused (
):
Healthcare > Medical Devices
Target
Focused (
):
Healthcare > Medical Devices > Orthopedics > Surgical
Business Description
Buyer
Baxter International Inc. (Baxter) is a global, diversified healthcare company. The Company, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. It operates in three segments: The BioScience, Medication Delivery and Renal segments. Baxter is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors? offices, clinical and medical research laboratories, and by patients at home under physician supervision. Baxter manufactures products in 27 countries and sells them in more than 100 countries.
Target
ArthroCare Corporation (ArthroCare) is a medical device company, which develops, manufactures and markets surgical products, which are based on its patented Coblation technology. The Company?s business consists of two product areas: Sports Medicine, and Ear Nose and Throat (ENT). It also manufactures and sells products based on its technology for other procedures, such as certain spine procedures. It?s Sports Medicine, ENT and Other products are marketed and sold through two principal geographic distribution channels: Americas (North and South America) and International (all other geographies). Many of its products are based on Coblation technology, which uses bipolar radiofrequency energy to generate a focused plasma field to remove and shape soft tissues, such as cartilage and tendons. Its bipolar Coblation devices also include both an active and return electrode at the tip but and apply electrical energy in a conductive medium at the surgical site.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
Gross Margin %
|
50.62 | 70.85 |
Operating Margin %
|
20.4 | 20.02 |
Quick Ratio
|
0.95 | 4.33 |
Current Ratio
|
1.67 | 5.96 |
Coverage Ratio
|
0.01 | n/a |
| Total Assets | 18,784.0 | 468.8 |
| Return on Equity % | 134.84 | 26.07 |
| Return on Assets % | 48.28 | 22.26 |
Cash+ ST Inv. Per Share
|
4.04 | 5.79 |
| Total Debt | 5,209.0 | 0.0 |
| Total Debt to Equity % | 77.46 | 0 |
| Total Debt to Tangible Equity % | 156.9 | 0 |
Debt to Asset %
|
27.73 | 0.00 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
Healthcare Services |
|
|
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
|
|
|
Medical Devices |
|
|
Anesthesiology
The Anesthesiology Subsector includes medical devices that deliver and monitor anesthetics.
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
Ear/Nose/Throat (ENT)
The Ear/Nose/Throat Subsector includes medical devices that diagnose and treat conditions affecting these anatomical regions.
|
|
|
Gastroenterology
The Gastroenterology Subsector includes medical devices that diagnosis and treat conditions affecting the stomach and intestinal tract.
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
|
|
|
Ophthalmology
The Ophthalmology Subsector includes medical devices that diagnose and treat eye disorders.
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
Respiratory
The Respiratory Subsector includes medical devices that diagnose and treat respiratory diseases.
|
|
|
Transfusion Medicine
The Transfusion Medicine Subsector includes medical devices and accessories that prepare or implement blood transfusion.
|
|
|
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
|
|
|
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
|
|
|
Nutritional Health |
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
Outsourced Biomedical Services |
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Upper Respiratory |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
Angina |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Arrhythmia |
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Buyer Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
Heart Failure (HF) |
|
|
Complications |
|
|
Edema |
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
Myocardial Infarction (MI) |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Vascular Disorders |
|
|
Deep Vein Thrombosis (DVT) |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
Hypertension |
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
Hypovolemia |
|
|
Plasma Volumizers |
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat a decrease in circulating fluid (plasma) in the body by increasing plasma volume.
Buyer Products:
|
|
|
Thromboembolism |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Platelet Aggregation Inhibitors |
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Buyer Products:
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
Digestive System |
|
|
Gastrointestinal Tract Disorders |
|
|
Gastroesophageal Disorders |
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
|
|
|
Nausea/Vomiting |
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
Endocrinology/Metabolism |
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Hematology |
|
|
Hemophilia |
|
|
Hemophilia A |
|
|
Clotting Agents
Therapeutics that aid in blood coagulation.
Buyer Products:
|
|
|
Hemophilia B |
|
|
Clotting Agents
Therapeutics that assist in blood coagulation.
Buyer Products:
|
|
|
Von Willebrand Disease |
|
|
Recombinant Factor Therapy
Therapeutics that treat the clotting disorder caused by Von Willebrand factor (vWF) deficiency by supplying a recombinant form of the Von Willebrand factor (vWF).
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
Anemia |
|
|
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
Serum Factor Disorders |
|
|
Hypoalbuminemia |
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat low levels of serum albumin.
Buyer Products:
|
|
|
Immunology |
|
|
Autoimmune Disorders |
|
|
Arthritis |
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
Idiopathic Thrombocytopenia Purpura (ITP) |
|
|
Immunoglobulins
Therapeutics that treat a decrease in platelets by neutralizing autoantibodies with therapeutic antibodies.
Buyer Products:
|
|
|
Kawasaki Syndrome |
|
|
Immunoglobulins
Therapeutics that treat Kawasaki Syndrome by neutralizing autoantibodies with therapeutic antibodies.
Buyer Products:
|
|
|
Immune Deficiency Disorders |
|
|
Primary Immunodeficiency Diseases |
|
|
Immunoglobulins
Therapeutics that treat primary immunodeficiency diseases by providing the body with therapeutic antibodies.
Buyer Products:
|
|
|
Immunoglobulins/Hyaluronic Acid
Therapeutics that treat primary immunodeficiency diseases by providing therapeutic antibodies administered simultaneously with hyaluronic acid.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
Infectious Diseases |
|
|
Bacterial |
|
|
Antibacterial Agents |
|
|
Broad Spectrum |
|
|
Antibiotics |
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
Narrow Spectrum |
|
|
Respiratory System |
|
|
Tuberculosis |
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
Vaccines |
|
|
Bacterial |
|
|
Combination |
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Buyer Products:
|
|
|
Mycological (Fungal) |
|
|
Antifungal Agents |
|
|
Narrow Spectrum |
|
|
Dermatology |
|
|
Tinea Barbae |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Capitis |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Corporis (Ringworm) |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Cruris (Jock Itch) |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Pedis |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Unquium |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Tinea Versicolor |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
Nervous System |
|
|
Cryptococcal Meningitis |
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
Esophageal Candidiasis |
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Oropharyngeal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pharynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Urology |
|
|
Vaginal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
Viral |
|
|
DNA Viruses |
|
|
Herpesvirus |
|
|
Herpes Simplex Type 1 |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Herpes Simplex Type 2 |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Varicella Zoster |
|
|
Herpes Zoster (Shingles) |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Varicella (Chickenpox) |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
Vaccines |
|
|
Viral |
|
|
Single Target |
|
|
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.
Buyer Products:
|
|
|
Musculoskeletal System |
|
|
Skeletal Disorders |
|
|
Joint Disorders |
|
|
Osteoarthritis (OA) |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
Neurology |
|
|
Neurological Disorders |
|
|
Alzheimer`s Disease |
|
|
Immunoglobulins
Therapeutics that treat and manage Alzheimer's disease by providing a therapeutic protein.
Buyer Products:
|
|
|
Epilepsy |
|
|
Status Epilepticus |
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
Headaches |
|
|
Vascular (Migraine) |
|
|
Prophylactic Treatments |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Buyer Products:
|
|
|
Neuromuscular Disorders |
|
|
Myasthenia Gravis (MG) |
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Buyer Products:
|
|
|
Neuropathy |
|
|
Immunoglobulins
Therapeutics that treat neuropathy by providing a broad spectrum of opsonic and neutralizing IgG antibodies.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Oncology |
|
|
Breast Cancer |
|
|
Localized |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage breast cancers by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Hematology |
|
|
Leukemia (White Blood Cell Cancer) |
|
|
Lymphoid |
|
|
Acute |
|
|
Lymphoblastic |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of immature lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Lymphocytic |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Chronic |
|
|
Lymphocytic (CLL) |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Immunoglobulins
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by providing a therapeutic protein.
Buyer Products:
|
|
|
Myeloid |
|
|
Acute |
|
|
Monocytic |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mononuclear cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Myelogenous (AML) |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage rapidly progressing cancers of myelogenous cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Chronic |
|
|
Granulocytic |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of myelocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
Cutaneous T-Cell Lymphoma (CTCL) |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage T-Cell lymphomas of the skin by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Hodgkin`s Disease |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of mature antibody producing white blood cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Neurology |
|
|
Brain Cancer |
|
|
Neuroblastoma |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of primitive ganglion cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Opthalmology |
|
|
Retinoblastoma |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of the retina by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Urology |
|
|
Ovarian Cancer |
|
|
Adenocarcinoma |
|
|
Alkylating Agents |
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
Pain Management |
|
|
Anesthesia |
|
|
General (Systemic) |
|
|
Adjunctive |
|
|
Ether-Based Agents
Therapeutics that result in anesthesia due to interfering with the physiological functioning of nerve cell membranes in the brain.
Buyer Products:
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Buyer Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Reversal |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Buyer Products:
|
|
|
Narcotics |
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
Non-Narcotics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
Respiratory System |
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
Emphysema |
|
|
Congenital |
|
|
Proteinase Inhibitors
Therapeutics that treat emphysema by providing certain proteins. The body's lack of ability to manufacture these proteins results in the disease state.
Buyer Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Upper Respiratory Tract Disorders |
|
|
Coughs/Colds |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
Antihistamines/Decongestants/Opioids
Therapeutics that treat coughs and colds by suppressing histamine-related inflammation, preventing congestion and altering both the perception and emotional response to pain.
Buyer Products:
|
|
|
Antihistamines/Opioids
Therapeutics that treat coughs and colds by suppressing histamine-related inflammation and altering both the perception and emotional response to pain.
Buyer Products:
|
|
|
Surgery |
|
|
Cardiovascular System |
|
|
Thrombosis |
|
|
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
General |
|
|
Complications |
|
|
Hemorrhage |
|
|
Fibrinolysis Inhibitors
Therapeutics that treat complications involving bleeding after surgical procedures by inhibiting the breakdown of fibrin in blood clots.
Buyer Products:
|
|
|
Thrombosis |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Thrombin Inhibitors
Therapeutics used to control and treat blood clots by preventing the action of thrombin, a key enzyme involved in the clot formation process.
Buyer Products:
|
|
|
Musculoskeletal System |
|
|
Deep Vein Thrombosis (DVT) |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
Neurology |
|
|
Seizures |
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
Urology |
|
|
Urological Disorders |
|
|
Bladder |
|
|
Cystitis |
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Buyer Products:
|
|
|
Healthcare Services |
|
|
Patient Care |
|
|
Ambulatory/Outpatient |
|
|
Specialized |
|
|
Dialysis Services
The process of cleansing the blood of end stage renal disease patients (ESRD) through the use of a semipermeable membrane, which allows waste products to pass but retains most of the blood's normal constituents. Dialysis services can be provided in outpatient settings, in patients' home, or in hospitals as a contractor.
Buyer Products:
|
|
|
Medical Devices |
|
|
Anesthesiology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Systems |
|
|
Consciousness Monitoring
Systems designed to monitor the effect of anesthesia on patients during surgery.
Buyer Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Delivery Systems |
|
|
Gas |
|
|
Breathing Accessories
Ancillary devices used to aid the administering of inhaled anesthetics, such as breathing bags and breathing masks.
Buyer Products:
|
|
|
Breathing Circuits
Devices which assist in physical mechanism of breathing.
Buyer Products:
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
Fluid Administration Sets
Intravenous fluid administration sets used to deliver anesthesia.
Buyer Products:
|
|
|
Pumps/Systems
Devices used to pump intravenous fluids at a consistent programmed rate.
Buyer Products:
|
|
|
Viscoelastics
Materials that can be applied to the skin and decrease resistance of to injected drugs.
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Delivery Systems |
|
|
Epidural
Devices used to inject anesthetic into the epidural space to numb the legs and abdomen, which include catheters, needles, syringes and other prepackaged kits.
Buyer Products:
|
|
|
Nerve Block
Devices used to assist in the delivery of nerve block anesthetic, which include catheters, needles and other prepackaged kits.
Buyer Products:
|
|
|
Spinal
Devices used to inject anesthetic into the spine, which include catheters, needles and other prepackaged kits.
Buyer Products:
|
|
|
Cardiology |
|
|
Surgical |
|
|
General Procedure |
|
|
Accessories |
|
|
Probes
A blunt needle-like devices that is used to push aside tissue and explore.
Buyer Products:
|
|
|
Vessel Closure
Devices used to close heart blood vessels.
Buyer Products:
|
|
|
Grafts |
|
|
Patches |
|
|
Porcine/Bovine Bioprosthesis
Pieces of bioengineered material used as a graft in cardiac surgery.
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Coronary Artery Bypass Graft (CABG) |
|
|
Invasive (Open Heart) |
|
|
Accessories
Various instruments used to assist in open heart bypass surgery, such as sutures, needles and vessel occluders.
Buyer Products:
|
|
|
Manual Instruments
Various devices used to perform open heart bypass surgery that do not require electrical power, such as heart positioners, stabilizers and retractors.
Buyer Products:
|
|
|
Shunts
Devices used to divert blood flow in order to perform surgical procedure.
Buyer Products:
|
|
|
Drug Delivery |
|
|
Infusion Therapy |
|
|
Accessories |
|
|
Admixture Systems
Medical systems designed to combine multiple medications for delivery to the patients
Buyer Products:
|
|
|
Closed Blood Sampling Systems
Sampling systems which do not use needles to access infusion systems to obtain a blood sample.
Buyer Products:
|
|
|
Filtration Products
Device used to filter fluids for infusion.
Buyer Products:
|
|
|
Fluid Administration/Extension Sets
Filtered IV sets designed for infusion therapy.
Buyer Products:
|
|
|
Fluid Warmers
Medical devices used to maintain the warmth of the medical products prior to and during the infusion process.
Buyer Products:
|
|
|
Needleless Fluid Administration/Extension Sets
Valve systems designed to work without needles to prevent patient injuries.
Buyer Products:
|
|
|
Pump Sets
Pump sets designed specifically for infusion therapy.
Buyer Products:
|
|
|
Delivery Systems |
|
|
Elastomeric Infusors
Infusion delivery system designed for small-volume fluid transmission (home use).
Buyer Products:
|
|
|
Pumps |
|
|
Multiple Channel
Multiple channel pump designed to deliver more than one infusion therapy to patients.
Buyer Products:
|
|
|
Single Channel
Single channel pump designed to deliver only one infusion therapy to patients.
Buyer Products:
|
|
|
Syringe
Syringe used in place of a pump to deliver infusion therapy.
Buyer Products:
|
|
|
Integrated/Comprehensive Systems
Complete infusion systems that include pumps, monitoring devices and other accessories.
Buyer Products:
|
|
|
Vascular Access |
|
|
Peripheral Intravenous Catheters |
|
|
Infusion Sets
Complete infusion sets containing peripheral intravenous catheters.
Buyer Products:
|
|
|
Standard
Non-ported peripheral intravenous catheters.
Buyer Products:
|
|
|
Ear/Nose/Throat (ENT) |
|
|
Surgical |
|
|
Procedure/Region Specific |
|
|
Nose/Sinus |
|
|
Accessories |
|
|
Nasal Packing
Material used to block up the nasal passages
Target Products:
|
|
|
Instruments |
|
|
Electrical |
|
|
Electrosurgical |
|
|
Bipolar Attachments
An electrosurgical system that has two electrodes in the tip of the instrument to allow for electrical current to flow out one electrode and then back into the other at the site of contact.
Target Products:
|
|
|
Endoscopy |
|
|
Hand Pieces/Drills
Devices that allow the user to manipulate an endoscope, bore holes, or perform other surgical procedures.
Target Products:
|
|
|
Throat |
|
|
Instruments |
|
|
Electrical |
|
|
Electrosurgical |
|
|
Bipolar Attachments
Handpieces that are attached to a bipolar electrosurgical generator for use in throat surgery.
Target Products:
|
|
|
Gastroenterology |
|
|
Treatment |
|
|
Stomach |
|
|
Enteral Feeding |
|
|
Sets
Complete instrument systems that perform enteral feeding procedures.
Buyer Products:
|
|
|
Tubes |
|
|
Feeding
A tube that carries food to the stomach.
Buyer Products:
|
|
|
General Surgery |
|
|
Invasive |
|
|
Instruments |
|
|
Electrical |
|
|
Electrosurgical |
|
|
Attachments/Handpieces |
|
|
Bipolar
Electrosurgical equipment that utilize bipolar technology in which the electric current flows between the two tips of the instrument, including cutting/coagulating probes, forceps and clamps.
Target Products:
|
|
|
Generators |
|
|
Bipolar
Electrical generators designed to produce current for bipolar electrosurgical equipment
Target Products:
|
|
|
Procedure/Region Specific |
|
|
Lungs |
|
|
Surgical Sealants |
|
|
Stapling Buttresses
Strips applied to surfaces of the lung to allow closure via stapling of the two surfaces
Buyer Products:
|
|
|
Surgical-Site Treatments |
|
|
Anti-Adhesives/Anti-Scarring |
|
|
Gels
Gel-based products applied during interventional procedures to prevent adhesion to medical devices or to prevent scarring of the surgical site
Buyer Products:
|
|
|
Membranes
Membrane-based products applied during interventional procedures to prevent adhesion to medical devices or to prevent scarring of the surgical sites
Buyer Products:
|
|
|
Sealants |
|
|
Adhesives
Glue based products used to seal tissue during surgical procedures
Buyer Products:
|
|
|
Hemostatic |
|
|
Delivery Systems
Medical devices designed to deliver hemostatic sealants to the surgical site
Buyer Products:
|
|
|
Sponges
Microfibrillar sponge used when conventional hemostasis procedures are not effective.
Buyer Products:
|
|
|
Topical
Topical mixture used when conventional hemostasis procedures are not effective.
Buyer Products:
|
|
|
Tissue |
|
|
Stapling Buttresses
Devices used to reinforce tissue staples and to prevent leakage from staple lines.
Buyer Products:
|
|
|
Minimally Invasive |
|
|
Instruments |
|
|
Manual |
|
|
Endoscopic Instruments
Manual instruments used during laproscopic procedures, such as forceps, retractors, clips, cutters and other similar items.
Buyer Products:
|
|
|
Medical Supplies |
|
|
Diagnostic |
|
|
Clinical Examination |
|
|
Basic Examining Tools
Medical instruments used to examine and monitor basic physiological functions, such as reflex, blood pressure, heart rate, and pulmonary capacity. These instruments include stethoscopes, sphygmomanometers, percussion hammers and other similar items.
Buyer Products:
|
|
|
Furnishings |
|
|
Medical Supplies Management |
|
|
Pharmaceutical Management Systems
Automated inventory management and dispensing systems for medicines (including both modules and systems).
Buyer Products:
|
|
|
Safety and Sterilization |
|
|
Safety |
|
|
Waste Management
Products used to control and contain biohazardous materials, such as chemical waste, fluid waste, and solid waste. These products may include bags, containers, and other more advanced waste treatment systems.
Buyer Products:
|
|
|
Treatment |
|
|
Wound Management |
|
|
Cleaning/Healing Devices
Devices used to clean and facilitate healing of wounds, such as bandages, dressings, cleansers, anti-infective ointments, sponges, cold compresses and other similar items.
Buyer Products:
|
|
|
Drainage/Hydration
Medical devices designed to irrigate, moisturize and remove excess fluids from wounds and wound surface.
Target Products:
|
|
|
Neurology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Monitors |
|
|
Electroencephalograph (EEG) |
|
|
Intraoperative
An electroencephalograph that is used during surgery.
Buyer Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Instruments |
|
|
Manual Instruments
Devices that are used in neurological surgery that do not require electrical power, such as drills, curettes, dissectors, forceps, hooks, retractors, bisectors and other similar items.
Target Products:
|
|
|
Surgical Sealants
A glue like material, made up of biomaterials, that is used to close up surgical incisions.
Buyer Products:
|
|
|
Procedure Specific |
|
|
Nerve Regeneration
Devices that assist in the re-growth of injured nerves in the brain or spinal cord.
Buyer Products:
|
|
|
Region Specific |
|
|
Brain |
|
|
Dural Grafts
Grafts designed to replace and/or repair damaged or diseased dural tissue.
Buyer Products:
|
|
|
Obstetrics/Gynecology |
|
|
Surgical |
|
|
General Procedure |
|
|
Endoscopic |
|
|
Laparoscopic |
|
|
Manual Instruments
Surgical instruments designed for use in conjunction with laparoscopy that do not require electrical power, such as cannulas, trocars, clamps, morcellators, needles, scissors and other similar items.
Buyer Products:
|
|
|
Region Specific |
|
|
Pelvic Floor Reconstruction
Indicated for restructuring pelvic cavity.
Buyer Products:
|
|
|
Ophthalmology |
|
|
Surgical |
|
|
Procedure/Region Specific |
|
|
Cataract |
|
|
Viscoelastics
Material that can be applied to decrease resistance between two parts of the eye and promote healing and repair of damaged eye tissue.
Buyer Products:
|
|
|
Orthopedics |
|
|
Surgical |
|
|
General Procedure |
|
|
Invasive |
|
|
Instruments |
|
|
Electrical |
|
|
Handpiece/Drill
Instruments used to drill holes in bone.
Target Products:
|
|
|
Manual Instruments
Mechanical instruments used in musculoskeletal surgical procedures, such as blades, curettes, broaches, shavers, elevators, tensioners, osteotomes, retractors, rongeurs and other similar items.
Target Products:
|
|
|
Minimally Invasive/Arthroscopic |
|
|
Instruments |
|
|
Electrical |
|
|
Electrosurgical |
|
|
Bipolar Attachments
Electrosurgical equipment in which the electric current flows between the two tips of the instrument and do not require grounding pads to surgically process live tissues.
Target Products:
|
|
|
Manual Instruments
Mechanical instruments used in arthroscopic surgical procedures, such as biopsy systems, blades, scalpels, bone harvesters, forceps, clamps, bisectors, suture punch and other similar items.
Target Products:
|
|
|
Procedure Specific |
|
|
Bone Loss Reconstruction |
|
|
General |
|
|
Bone Fillers
Devices used to fill the formed bone cavity with hardening material.
Buyer Products:
|
|
|
Fixation |
|
|
Bone |
|
|
External |
|
|
Specific |
|
|
Hip/Femur
External fixation devices used to immobilize hip or femur fractures.
Target Products:
|
|
|
Soft Tissue |
|
|
Anchors/Screws |
|
|
Absorbable |
|
|
Specific |
|
|
Knee
Absorbable anchors/screws used to attach soft tissue to the knee bones.
Target Products:
|
|
|
Metallic |
|
|
General
Metal devices used to attach soft tissue to the bone in a variety of regions.
Target Products:
|
|
|
Specific |
|
|
Knee
Metal devices used to attach soft tissue to the knee bones.
Target Products:
|
|
|
Shoulder
Metal devices used to attach soft tissue to the shoulder bones.
Target Products:
|
|
|
Suture/Hook Repair Systems |
|
|
Specific |
|
|
Shoulder
Suture anchors used to attach soft tissue to the shoulder bones.
Target Products:
|
|
|
Region Specific |
|
|
Knee |
|
|
Instruments |
|
|
Manual |
|
|
Graft Fixation/Harvesting Systems
Devices used to attach grafts to existing tissue.
Target Products:
|
|
|
Tunnel Placement Guides
Devices used to guide the placement of knee tunnels for ligament insertion during knee ligament repair surgeries
Target Products:
|
|
|
Respiratory |
|
|
Treatment |
|
|
Assisted Breathing |
|
|
Intubation |
|
|
Breathing Circuits
Instrument used to measure respiratory parameters such as pressure.
Buyer Products:
|
|
|
Transfusion Medicine |
|
|
Blood Collection |
|
|
Apheresis Systems |
|
|
Plasma
Systems which separate and collect the plasma component of human blood while returning other blood components to the donor.
Buyer Products:
|
|
|
Platelets
Systems which separate and collect the platelet cell component of human blood while returning other blood components to the donor.
Buyer Products:
|
|
|
Red Blood Cells
Systems which separate and collect the red cell component of human blood while returning other blood components to the donor.
Buyer Products:
|
|
|
Blood Washers
Instruments used to wash blood cells in preparation for usage; they are often used to prepare frozen red blood cells for transfusion.
Buyer Products:
|
|
|
Filtration Systems
Medical devices used to filter leukocytes from blood during the transfusion process.
Buyer Products:
|
|
|
Viral Inactivation |
|
|
Plasma
Medical devices and technology which destroy infectious agents such as viruses in donor plasma without damaging the integrity of the plasma proteins.
Buyer Products:
|
|
|
Platelets
Medical devices and technology which destroy infectious agents such as viruses in blood products (platelets) without damaging the integrity of the donor platelet cells.
Buyer Products:
|
|
|
Red Blood Cells
Medical devices and technology which destroy infectious agents such as viruses in donor blood without damaging the integrity of the donor red blood cells.
Buyer Products:
|
|
|
Urology |
|
|
Surgical |
|
|
General Procedure |
|
|
Minimally Invasive/Cystoscopy |
|
|
Irrigation Pumps/Systems
Surgical instruments that pump fluids to irrigate/moisten the surface of the urinary organs
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Incontinence |
|
|
Female |
|
|
Urethral Sling
Devices designed to inhibit urine flow out of the bladder.
Buyer Products:
|
|
|
Treatment |
|
|
Renal |
|
|
Hemodialysis |
|
|
Components |
|
|
Concentrates
Chemicals used in hemodialysis.
Buyer Products:
|
|
|
Dialysate Parameter Monitors
Medical products used to monitor parameters such as fluid pressure, concentration, pH etc. during dialysis procedures.
Buyer Products:
|
|
|
Filtration |
|
|
Dialyzers
The instrument or medium used to effect chemical dialysis which allows for the diffusion of waste products and excess water into a dialysate solution.
Buyer Products:
|
|
|
Hemofilters
Filters used to separate the blood from the waste components during dialysis
through a convection process by creating negative pressure to draw out solute particles without using a dialysate solution.
Buyer Products:
|
|
|
Systems
A complete set of devices that act as a kidney to remove waste from the circulatory system.
Buyer Products:
|
|
|
Peritoneal Dialysis |
|
|
Components |
|
|
Solutions
Chemical agents used in peritoneal dialysis.
Buyer Products:
|
|
|
Systems |
|
|
Automated Peritoneal Dialysis (APD)
Complete set of instruments and devices that cycle solution to and from the patient's peritoneum during sleep.
Buyer Products:
|
|
|
Continuous Ambulatory (CAPD)
Complete set of instruments and devices that perform peritoneal dialysis that can be moved around with the patient.
Buyer Products:
|
|
|
Vascular |
|
|
Surgical |
|
|
General Procedure |
|
|
Accessories |
|
|
Introducers
Devices used to provide percutaneous introduction of catheters, interventional devices, and temporary pacing leads into the vasculature.
Buyer Products:
|
|
|
Vessel Closure
Devices used to close and repair vascular structures, including both complete systems and associated clamps, felts and pledgets.
Buyer Products:
|
|
|
Grafts |
|
|
Patches |
|
|
Bioprosthesis
Surgical grafts produced from biological material, often from tissues that are bovine or porcine in origin.
Buyer Products:
|
|
|
Instruments |
|
|
Manual Instruments
Devices used to perform general vascular surgery that do not require electrical power, including balloon dissection systems, retractors, forceps, clamps, scissors, needles, tunnelers, valvuotomes and other similar surgical items.
Buyer Products:
|
|
|
Nutritional Health |
|
|
Dietary/Naturopathic Supplements |
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
Outsourced Biomedical Services |
|
|
Development/Manufacturing Services |
|
|
Contract Manufacturing Organizations (CMO) |
|
|
Biopharmaceutical OEM |
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Covidien PLC
|
|
n/a | 27,247.823 | 13.91 | 12.70 | 2.30 | 2.27 | n/a | |
Fresenius Medical Care AG & Co. KGaA
|
|
n/a | 20,660.517 | 22.69 | 16.31 | 1.59 | 1.46 | n/a | |
Hospira Inc
|
|
n/a | 5,496.746 | n/a | 15.85 | 1.37 | 1.38 | 3.42 | |
Moog Inc
|
|
n/a | 1,815.559 | 12.65 | n/a | 0.75 | n/a | 5.36 | |
Akorn Inc
|
|
n/a | 1,206.683 | 25.70 | 25.29 | 7.39 | 4.48 | 28.99 | |
NxStage Medical Inc
|
|
n/a | 840.231 | n/a | -58.30 | 3.76 | 3.58 | 9.63 | |
ICU Medical Inc
|
|
n/a | 751.608 | 28.37 | 20.82 | 2.45 | 2.34 | 2.30 | |
Sagent Pharmaceuticals Inc
|
|
n/a | 440.923 | n/a | 16.99 | 2.89 | 1.97 | 3.23 | |
Kensey Nash Corp
|
|
n/a | 328.386 | 34.49 | 23.92 | 3.91 | 3.71 | 3.43 | |
Nymox Pharmaceutical Corp
|
|
n/a | 263.197 | n/a | 26.29 | 106.97 | n/a | n/a | |
Unilife Corporation
|
|
n/a | 242.636 | n/a | -5.40 | 48.62 | 32.01 | 5.64 | |
YM Biosciences Inc
|
|
n/a | 240.425 | n/a | -6.67 | 139.23 | 203.96 | 4.31 | |
Biotime Inc
|
|
n/a | 182.771 | n/a | n/a | 27.03 | n/a | 18.23 | |
Celldex Therapeutics Inc
|
|
n/a | 182.328 | n/a | -4.08 | 19.86 | 20.17 | 2.45 | |
Cryolife Inc
|
|
n/a | 142.792 | 21.56 | 29.94 | 1.17 | 1.11 | 1.46 | |
| Target | |||||||||
Johnson & Johnson
|
|
n/a | 176,314.376 | 10.12 | 12.61 | 1.55 | 2.65 | n/a | |
Medtronic Inc
|
|
n/a | 40,348.005 | 11.93 | 10.50 | 2.46 | 2.46 | 8.89 | |
Stryker Corp
|
|
n/a | 20,651.294 | 15.58 | 12.99 | 2.49 | 2.38 | 4.93 | |
Smith & Nephew PLC
|
|
n/a | 8,659.748 | 4.77 | 11.92 | 2.03 | 2.03 | 5.19 | |
Tornier N.V.
|
|
n/a | 821.805 | n/a | -304.00 | 3.09 | 2.99 | 4.48 | |
Conmed Corp
|
|
n/a | 785.942 | 720.24 | 15.57 | 1.07 | 1.02 | 4.97 | |
Bacterin International Holdings Inc
|
|
n/a | 63.829 | 80.28 | -11.92 | 1.77 | 1.45 | 15.51 | |
Arthrex, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Biomet, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Olympus KK
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Honeywell International Inc
|
|
n/a | 45,810.995 | 21.10 | 13.02 | 1.23 | 1.19 | n/a | |
Pegasystems Inc
|
|
n/a | 1,241.101 | 134.85 | 40.09 | 2.92 | 2.48 | 9.71 | |
Nektar Therapeutics
|
|
n/a | 826.104 | n/a | -5.49 | 10.57 | 9.87 | 9.61 | |
Halozyme Therapeutics Inc
|
|
n/a | 773.002 | n/a | -12.49 | 13.81 | 34.72 | 9.54 | |
Medidata Solutions Inc
|
|
n/a | 690.930 | 17.15 | 31.68 | 3.56 | 3.17 | 7.25 | |
Healthstream Inc
|
|
n/a | 472.897 | 98.26 | 66.91 | 5.42 | 4.69 | 3.84 | |
CapLease Inc
|
|
n/a | 282.431 | n/a | 6.89 | 1.73 | 1.75 | 0.73 | |
Ligand Pharmaceuticals Inc
|
|
n/a | 242.963 | 41.62 | 65.11 | 5.63 | 5.23 | n/a | |
CRA International Inc
|
|
n/a | 215.085 | 16.97 | 13.59 | 0.73 | 0.70 | 1.73 | |
Dyax Corp
|
|
n/a | 154.047 | n/a | -4.88 | 2.96 | 2.96 | n/a | |
Flamel Technologie SA
|
|
n/a | 116.574 | n/a | -23.24 | 3.58 | 3.20 | n/a | |
Dialight PLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
P & I Personal & Informatik AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Celgene Corp
|
|
n/a | 32,478.877 | 22.53 | 16.39 | 6.51 | 5.96 | 5.34 | |
Davita Inc
|
|
n/a | 7,741.926 | 14.95 | 13.66 | 1.06 | 1.01 | n/a | |
Amylin Pharmaceuticals Inc
|
|
n/a | 3,772.803 | n/a | -13.67 | 5.80 | 5.49 | n/a | |
United Therapeutics Corp
|
|
n/a | 2,483.121 | 9.80 | 9.41 | 3.16 | 2.84 | 2.46 | |
Medicines Co
|
|
n/a | 1,165.046 | 5.19 | 19.87 | 1.37 | 2.15 | 2.99 | |
Threshold Pharmaceuticals
|
|
n/a | 306.635 | n/a | 619.00 | 982.74 | 8.49 | n/a | |
Cadence Pharmaceuticals Inc
|
|
n/a | 181.939 | n/a | -3.58 | 7.47 | 3.19 | 2.10 | |
Accentia Biopharmaceuticals Inc
|
|
n/a | 19.141 | n/a | n/a | 2.00 | n/a | n/a | |
The Olayan Group
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
PT Kalbe Farma Tbk
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Poniard Pharmaceuticals Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Sobhan Pharmaceutical Co
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
PT Enseval Putera Megatrading Tbk
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Suhail Bahwan Group (Holding) LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Acambis PLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
Wright Medical Group Inc
|
|
n/a | 823.947 | n/a | 105.60 | 1.63 | 1.72 | 1.73 | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Celgene Corp
|
|
n/a | 32,478.877 | 22.53 | 16.39 | 6.51 | 5.96 | 5.34 | |
Cardinal Health Inc
|
|
n/a | 14,896.420 | 14.43 | 13.20 | 0.14 | 0.14 | 7.97 | |
Davita Inc
|
|
n/a | 7,741.926 | 14.95 | 13.66 | 1.06 | 1.01 | n/a | |
Amylin Pharmaceuticals Inc
|
|
n/a | 3,772.803 | n/a | -13.67 | 5.80 | 5.49 | n/a | |
United Therapeutics Corp
|
|
n/a | 2,483.121 | 9.80 | 9.41 | 3.16 | 2.84 | 2.46 | |
Medicines Co
|
|
n/a | 1,165.046 | 5.19 | 19.87 | 1.37 | 2.15 | 2.99 | |
Nektar Therapeutics
|
|
n/a | 826.104 | n/a | -5.49 | 10.57 | 9.87 | 9.61 | |
Halozyme Therapeutics Inc
|
|
n/a | 773.002 | n/a | -12.49 | 13.81 | 34.72 | 9.54 | |
Momenta Pharmaceuticals Inc
|
|
n/a | 729.739 | 6.27 | -19.61 | 3.18 | 8.93 | n/a | |
Ziopharm Oncology Inc
|
|
n/a | 307.125 | n/a | -4.30 | 385.12 | 386.47 | 3.14 | |
Threshold Pharmaceuticals
|
|
n/a | 306.635 | n/a | 619.00 | 982.74 | 8.49 | n/a | |
Ligand Pharmaceuticals Inc
|
|
n/a | 242.963 | 41.62 | 65.11 | 5.63 | 5.23 | n/a | |
Cadence Pharmaceuticals Inc
|
|
n/a | 181.939 | n/a | -3.58 | 7.47 | 3.19 | 2.10 | |
Oncothyreon Inc
|
|
n/a | 173.433 | n/a | -7.59 | n/a | 8,608.67 | 4.19 | |
Flamel Technologie SA
|
|
n/a | 116.574 | n/a | -23.24 | 3.58 | 3.20 | n/a | |
Accentia Biopharmaceuticals Inc
|
|
n/a | 19.141 | n/a | n/a | 2.00 | n/a | n/a | |
Suhail Bahwan Group (Holding) LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
PT Enseval Putera Megatrading Tbk
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
EIS Eczacibasi Ilac Sanayi ve Ticaret A.S.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Sobhan Pharmaceutical Co
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
Fedex Corp
|
|
n/a | 27,850.476 | 13.70 | 13.31 | 0.66 | 0.64 | 1.97 | |
Smith & Nephew PLC
|
|
n/a | 8,659.748 | 4.77 | 11.92 | 2.03 | 2.03 | 5.19 | |
Wright Medical Group Inc
|
|
n/a | 823.947 | n/a | 105.60 | 1.63 | 1.72 | 1.73 | |
One Equity Partners
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Deutsche Post AG
|
|
n/a | n/a | n/a | 9.10 | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 13,997.0 | 605.7 | 14,602.7 |
Other Revenue
|
n/a | n/a | n/a |
| Total Revenue | 13,997.0 | 622.3 | 14,619.3 |
Cost of Revenue
|
6,912.0 | 181.4 | 7,093.4 |
SG&A Expense
|
3,111.0 | 253.6 | 3,364.6 |
Depreciation & Amortization
|
n/a | 4.0 | 4.0 |
Research & Development
|
1,001.0 | 22.2 | 1,023.2 |
Interest Expense
|
33.0 | n/a | 33.0 |
Other Operating Expense
|
5.0 | 11.0 | 16.0 |
Unusual Expense (Income)
|
79.0 | 13.8 | 92.8 |
| Total Expenses | 11,141.0 | 497.7 | 11,638.7 |
Operating Income
|
2,856.0 | 124.6 | 2,980.6 |
| Non Operating Items | |||
Interest Expense (Inc.), Net Non-Oprtng
|
-15.0 | n/a | -15.0 |
Other, Net
|
-17.0 | -0.8 | -17.8 |
| Income Before Taxes | 2,810.0 | 35.9 | 2,845.9 |
| Income Taxes | 543.0 | 9.9 | 552.9 |
| Income After Taxes | 2,267.0 | 26.1 | 2,293.1 |
| Minority Interest (IS) | -25.0 | n/a | -25.0 |
Net Income - Excl. Xord. Items
|
2,242.0 | 26.1 | 2,268.1 |
| Discontinued Operations | n/a | 3.5 | 3.5 |
Net Income - Incl. Xord. Items
|
2,242.0 | 29.6 | 2,271.6 |
| Preferred Dividends | n/a | -4.7 | -4.7 |
Income Avail. to Common
|
2,242.0 | 24.9 | 2,266.9 |
| Share Items | |||
Basic Avg. Shares Outstanding
|
559.0 | 27.6 | 586.6 |
Basic EPS - Excl. Xord. Items
|
3.97 | 0.78 | 3.87 |
Basic EPS - Incl. Xord. Items
|
3.97 | 0.84 | 3.87 |
| Full Dilution Adjustment | n/a | n/a | n/a |
| Fully Diluted Shares Outstanding | 563.0 | 28.0 | 591.0 |
F.D. EPS - Excl. Xord. Items
|
3.94 | 0.77 | 3.84 |
F.D. EPS - Incl. Xord. Items
|
3.94 | 0.83 | 3.84 |
| Dividends Per Common Share | 1.29 | n/a | 1.29 |
| Balance Sheet | |||
| Assets | |||
Cash and Equivalents
|
2,272.0 | 162.0 | 2,434.0 |
Accounts Receivable
|
2,341.0 | 49.2 | 2,390.2 |
Inventory
|
2,737.0 | 37.4 | 2,774.4 |
Prepayments and Advances
|
767.0 | 6.3 | 773.3 |
Other Current Assets
|
n/a | 35.9 | 35.9 |
Current Assets
|
8,117.0 | 290.7 | 8,407.7 |
PPE
|
11,117.0 | n/a | 11,117.0 |
Accum D&A
|
-5,480.0 | n/a | -5,480.0 |
PPE, Net
|
5,637.0 | 34.7 | 5,671.7 |
| Goodwill & Intangibles | 3,405.0 | 123.6 | 3,528.6 |
| Other Assets | n/a | n/a | n/a |
Other LT Assets
|
1,625.0 | 19.8 | 1,644.8 |
| Total Assets | 18,784.0 | 468.8 | 19,252.8 |
| Liabilities | |||
| Accounts Payable | n/a | 13.9 | 13.9 |
| Payable/Accrued | 4,059.0 | n/a | 4,059.0 |
| Accrued Expenses | n/a | 34.0 | 34.0 |
ST Debt
|
313.0 | n/a | 313.0 |
Curr Port of LTD & Cap Lease Oblg
|
485.0 | n/a | 485.0 |
| Other (Current) Liabilities | n/a | 0.9 | 0.9 |
Current Liab.
|
4,857.0 | 48.8 | 4,905.8 |
LT Debt
|
4,411.0 | n/a | 4,411.0 |
Total LT Debt
|
4,411.0 | n/a | 4,411.0 |
| Minority Interest (BS) | 239.0 | n/a | 239.0 |
| Deferred Taxes | n/a | 0.0 | 0.0 |
Other LT Liab.
|
2,552.0 | 19.7 | 2,571.7 |
Total Liabilities
|
12,059.0 | 68.5 | 12,127.5 |
| Shareholders Equity | |||
| Redeemable Preferred | n/a | 78.1 | 78.1 |
| Common Stock | 683.0 | 0.0 | 683.0 |
| Additional Paid in Capital | 5,766.0 | 403.5 | 6,169.5 |
| Retained Earnings | 9,831.0 | 20.7 | 9,851.7 |
| Treasure Stock | -7,106.0 | -106.9 | -7,212.9 |
| Other Equity | -2,449.0 | 5.0 | -2,444.0 |
Total Equity
|
6,725.0 | 400.3 | 7,125.3 |
Total Liab. & Equity
|
18,784.0 | 468.8 | 19,252.8 |
Shares Outstanding
|
554.3 | 27.6 | 582.0 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 1,679.0 | -0.7 | 1,678.3 |
| CF Depreciation | 687.0 | 24.4 | 711.4 |
| CF Deferred Taxes | 135.0 | -15.8 | 119.2 |
| Other Non-Cash Items | 494.0 | 13.1 | 507.1 |
| Change in Working Capital | -666.0 | -4.8 | -670.8 |
| Total Cash From Operating Activities | 2,446.0 | 13.9 | 2,459.9 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,001.0 | -13.5 | -1,014.5 |
| Other Investing Cash Flows | -757.0 | 7.7 | -749.3 |
| Total Cash From Investing Activities | -1,215.0 | -5.8 | -1,220.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -717.0 | n/a | -717.0 |
| Purchase Or Sale of Stock | -1,655.0 | 7.0 | -1,648.0 |
| Purchase and Retirement of Debt | 736.3 | n/a | 736.3 |
| Other Financing Cash Flow | 426.0 | n/a | 426.0 |
| Total Cash From Financing Activities | -449.0 | 7.1 | -441.9 |
| Exchange Rate Effects | -45.0 | -0.8 | -45.8 |
| Net Change in Cash | 737.0 | 14.4 | 751.4 |
| Cash Taxes Paid | 357.0 | n/a | 357.0 |
| Cash Interest Paid | 61.0 | n/a | 61.0 |
Covidien PLC